Abram Scientific, a Menlo Park, CA-based medical device company, has raised $11.75 million in a Series A funding round led by Octapharma AG.
The round also saw participation from existing and new investors affiliated with the University of Colorado Anschutz.
Read More:Chariot Defence Raises $34M in Series A Funding
The company plans to use the funds to speed up development of its portable CoagCare platform and support progress toward clinical milestones and FDA 510(k) clearance.
Abram Scientific, a medical device company developing next-generation coagulation diagnostics, created the CoagCare System—a rapid diagnostic platform for detecting and analysing coagulation disorders. Designed as a point-of-care meter with a single-use test card, the system uses proprietary technology to quickly and accurately measure blood viscoelasticity, and density. It evaluates the full coagulation process, from clot formation to fibrinolysis, in under 10 minutes, helping detect clotting or bleeding disorders, and guide therapy for optimal coagulation management.
Octapharma provides timely access to leading critical care therapies with a focus on improving patient outcomes. The company has advanced standards in critical care and developed new treatments for coagulation management. Its investment in emerging platforms demonstrates a focus on unmet clinical needs in haematology, and critical care, marking its first major move into diagnostics. This new direction aims to expand Octapharma’s products across the full continuum of patient care.
The CoagCare System is a major improvement over current coagulation diagnostic tools, such as thromboelastography and thromboelastometry, which typically take 30–60 minutes to measure clotting, including fibrinolysis. In contrast, CoagCare delivers a full assessment of blood coagulation in under 10 minutes from a single drop of blood. Its portable, vibration resistant design makes it ideal for remote or pre hospital use, such as in MEDEVAC helicopters and ambulances, where lab conditions aren’t available and quick, accurate transfusion decisions can save lives.
“Our mission is to help CoagCare guide life-saving therapies and transfusions, ensuring patients get the right treatment at the right time and dose,” said Abhishek Ramkumar, CEO and Founder of Abram Scientific. “Working with Octapharma and the University of Colorado gives us funding and expertise, helping us move faster and smarter and positioning CoagCare to transform current clinical practices.”
“We are excited to work with Abram Scientific on this next phase of technology development,” said Flemming Nielsen, President of Octapharma USA. “Abram’s approach has real potential to improve patient outcomes, and we are proud to support their progress. CoagCare can help clinicians deliver precise, goal-focused therapy—giving the right treatment at the right time and at the right dose. This is an important step for patient care and could influence clinical guidelines worldwide.”
“Uncontrolled bleeding is one of the leading and most preventable causes of early trauma death,” said Dr Vik Bebarta, Endowed Chair in Emergency Medicine at the University of Colorado Anschutz and Founding Director of The Centre for COMBAT Research. “We are excited to work with Abram Scientific to develop CoagCare, giving surgeons and emergency doctors the crucial information they need faster to make life-saving treatment decisions.”
About Abram Scientific
Founded by Dr Abhishek Ramkumar, CEO and inventor of the CoagCare platform, Abram Scientific is based in the San Francisco Bay Area. Its technology is protected by 17 U.S. and international patents, with more patents pending. The CoagCare System has not yet been cleared by the FDA for marketing in the United States.
Read More:Myrias Optics Raises $2.1 in Seed 1 Funding
